Myopia Control for Children in China: what's real, what's disputed
China has the largest childhood myopia programme in the world, and since 2018 it has been bending its own curve — national monitoring shows prevalence among children and adolescents fell 3.3 percentage points between 2018 and 2024, from a baseline near 53.6%. It is also where the world's first approved myopia-control drug was registered, and where red-light therapy was invented, scaled, and then reclassified into the strictest medical-device tier because the safety question is not settled. All of that is genuinely interesting. Almost none of it is a reason to put a child on a plane — and this guide is mostly about why, and about the narrow set of situations where a visit does earn its cost.
Myopia control is not a procedure. It is a multi-year relationship of measurements repeated every 3–6 months until the eye stops growing, with lens refits, drop titration and stopping decisions along the way. A single trip cannot deliver it, and a clinic that sells you one is selling the wrong product. If you do not have a clinician at home who will run the follow-up, do not start treatment abroad.
What childhood myopia care costs in China (published figures)
The figures below come from a nationwide urban cost-of-illness survey published in 2022 covering Anhui, Shanghai and Yunnan — that is, what Chinese families themselves pay out of pocket in the domestic system. We are quoting it rather than a partner price list on purpose: for these consumer items there is no international-department fee schedule we can verify, and inventing one would be worse than admitting the gap. Expect a private or VIP international clinic to charge more than these numbers, and treat them as an order of magnitude rather than a quote.
| Item | Anhui | Shanghai | Yunnan | Notes |
|---|---|---|---|---|
| Ortho-K / RGP lenses, per pair (discounted mean) | ¥4,673 | ¥5,902 | ¥6,466 | Medians ¥4,500–5,665 |
| Replacement interval | 1.2 yr | 1.8 yr | 1.6 yr | Mean reported |
| Annual running cost (solutions, checks) | ¥1,727 | ¥1,610 | ¥1,703 | On top of lenses |
| Ortho-K / RGP, all-in annual cost per person | ¥3,762 | ¥5,822 | ¥5,670 | ≈ US$520–810 |
| Soft contact lenses, annual per person | ¥951 | ¥1,740 | ¥1,268 | Not myopia-control by default |
| Ordinary spectacles, annual per person | ¥155 | ¥314 | ¥303 | Single-vision, no control effect |
US dollar conversions here use ¥7.2 to US$1 — stated so you can redo them at whatever rate applies when you read this. For reference, US orthokeratology is commonly quoted at US$1,000–4,000, with first-year averages around US$2,000–2,800 including topography and the fitting visits (published US consumer references, retrieved August 2026). So the Chinese domestic figure is roughly a quarter to a third of the American one — a real gap, but one measured against an annual, recurring, locally-delivered cost, which is exactly the kind of saving that does not survive being flown to.
The same survey found the annual cost of myopia care per myopic person was ¥458 (about US$69) against ¥35 for a non-myopic child — because the overwhelming majority of families buy correction and never buy control. Utilisation of orthokeratology among Chinese 10–19-year-olds was around 3% in a 2022 cross-sectional study, while roughly 80% wore ordinary single-vision spectacles or contact lenses that do nothing to slow progression. China's advantage is not that everyone there is treated. It is that everyone there is measured.
What China's national programme actually is
China stopped treating myopia as a refractive inconvenience and made it a government campaign. Since 2018, education, health and sport ministries have held provinces accountable for their myopia trends, paired with classroom lighting upgrades, school regulation and mandatory vision checks written into national health reporting. The 2018 national survey put overall prevalence at about 53.6% — roughly 36% in primary school, 71.6% in junior secondary and 81% in senior secondary. National monitoring then recorded a 3.3-percentage-point fall between 2018 and 2024, across a school system of roughly 280 million children.
In December 2025, thirteen departments led by the National Health Commission issued the Children and Adolescents' Five Health Promotion Action Plan (2026–2030), folding myopia into the Healthy China 2030 agenda with explicit targets:
| Cohort | 2030 target prevalence |
|---|---|
| Six-year-olds | around 3% |
| Primary school | below 32% |
| Junior secondary | below 60% |
| Senior secondary | below 70% |
The primary-school target tightened from the earlier plan's 38%, and the 2018 interim yardstick — at least a 0.5-point annual reduction — has been met and modestly exceeded. What converts policy into results is screening cadence: refractive checks at 24 and 36 months and again at ages 4, 5 and 6, six-monthly screening through kindergarten, twice per semester in school, all feeding electronic vision-health records, with at least two hours of daily outdoor time, screen-time limits and height-adjustable desks alongside. Chinese colleagues are candid that compliance is the hard part — outdoor time gets quietly subverted when children spend it in the shade doing worksheets — but universal repeated screening is the mechanism, and it is the part of the model most worth copying rather than travelling to.
The interventions, ranked by what the trials actually show
The treatment menu in China mirrors North America and Europe; what differs is availability, price and how early children enter the system. Figures below are from published randomised trials and describe populations, not any individual child.
| Intervention | Best published effect | Status in China |
|---|---|---|
| Daily outdoor time (2h+) | Most cost-effective of 13 strategies modelled; primarily delays onset | Written into the national plan |
| Highly aspherical lenslet (HAL) spectacles | 0.67 mm axial growth over 5 years vs 1.40 mm control; −1.75 D less progression | Widely available |
| DIMS defocus spectacles | 59% less progression, 60% less axial elongation at 2 years | Widely available |
| Orthokeratology (overnight lenses) | ~30–60% less progression; 0.25–0.27 mm less axial growth over 2 years | Established; ~3% uptake |
| Dual-focus / multifocal soft lenses | Supported by 3-year randomised data | Available |
| Low-concentration atropine (0.01–0.05%) | Dose-dependent in LAMP; contested elsewhere (see below) | 0.01% formally approved 2024 |
| Repeated low-level red light (RLRL) | Strong Chinese efficacy signals; safety unresolved | Class III since July 2024 |
| Traditional-medicine adjuncts | No accepted progression-control evidence | Provincial pilots only |
The direction of travel in Chinese practice is away from single interventions and towards combination therapy — an optical method plus a pharmacological one — with more frequent axial-length monitoring used to decide when to escalate. That is a clinician's judgement about a specific child, made from serial measurements, and no page can make it for you.
Red-light therapy: the China-specific one, and the reason for caution
Repeated low-level red-light therapy uses a desktop device emitting roughly 650 nm, typically viewed for about three minutes twice daily at home. It came out of Chinese research, it has produced some of the strongest efficacy numbers in the field, and it is the one intervention a family is far more likely to encounter in China than at home. It is also the one to be most careful about.
The laser emission is rated Class 1 under the IEC laser-safety standard, meaning it is considered eye-safe for incidental exposure, and systematic reviews have not identified irreversible structural damage. But Chinese researchers have reported decreased cone density within about 0.5 mm of the fovea and drusen-like lesions in some children — and the regulator responded by moving, not relaxing. Effective July 2024, the NMPA reclassified RLRL devices from Class II to Class III, its highest medical-device risk tier. That stripped oversight from provincial bodies, imposed national premarket review and now requires extensive safety and clinical evidence before any new device can be sold.
A regulator raising a device's risk class in the country where it was invented is a meaningful signal, and it is one most English-language marketing pages do not mention. The practical consequence is not "avoid" — many Chinese clinicians continue to use RLRL — but only inside a supervised protocol with OCT follow-up. Current devices are semiconductor-laser based, which is precisely why the scrutiny exists; LED alternatives with a potentially better safety profile are still under investigation. If anyone offers you a red-light device to take home without scheduled retinal imaging, that is not current practice, and it is the clearest single reason not to buy one on a short visit.
Atropine: approved in China, still argued about everywhere
In March 2024 the NMPA granted a drug approval certificate to Xingqi Eye Medicine's atropine sulfate eye drops (SQ-729) for slowing myopia progression in children — the first myopia-control drug anywhere to obtain a formal drug registration number on clinical-trial data. It was incubated in the China Eye Valley cluster in Wenzhou's Longwan district, a full-industry-chain eye-health complex built jointly by the district government and the Eye Hospital of Wenzhou Medical University, which now hosts more than 710 enterprises.
Regulatory approval is not scientific consensus, and the trials genuinely disagree:
| Trial | What it found for low-dose atropine |
|---|---|
| LAMP (Hong Kong) | 0.05%, 0.025% and 0.01% all beat placebo, dose-dependently |
| CHAMP (North America / Europe) | 0.01% produced more responders than placebo, 28.5% vs 17.5%; weaker effect at 0.02% |
| MOSAIC (Ireland) | 0.01% reduced progression 15.9% and axial growth 17.5% at 2 years |
| PEDIG (US) | No meaningful benefit of 0.01% over placebo at 2 years |
| JAMA Ophthalmology 2025 RCT | 0.04% may outperform both ortho-K and 0.01% on axial control |
What remains unsettled: the optimal concentration, how long to treat, how much rebound follows stopping, and the stopping rules themselves. There is also a real and unresolved argument about how aggressively to treat a low-risk, slowly-progressing child at all — early protection against overmedicalisation and years of daily compliance. Any clinic that presents atropine as a settled answer has skipped the part of the literature that matters most to your child.
Ask for axial length, not the prescription
The single most useful thing in this guide: the number to track is axial length in millimetres, not the dioptres on the spectacle order. The prescription describes what the child needs to see today. Axial length describes how much the eye has physically grown, and eye growth is what drives the lifetime risks that make childhood myopia a medical problem rather than a shopping one — retinal detachment, myopic maculopathy, glaucoma and irreversible vision loss.
Age of onset is the strongest single predictor of adult high myopia: a child who becomes myopic at seven or eight carries a lifetime high-myopia risk above 50%. That is why Chinese practice has moved upstream, screening toddlers to protect hyperopic reserve before myopia starts, and why the national framing shifted from "how many children wear glasses" to "how many are progressing into high myopia and long axial lengths". Plateauing prevalence is not the same as low prevalence.
1. What is my child's axial length today, and what were the last two readings? 2. How does that rate of growth compare with the age-specific normal curve? 3. What would make you escalate or change treatment, and when would you next measure? 4. If we start this and travel home, who runs the follow-up and what exactly do they need from you? A clinic that cannot answer the fourth is not equipped for an international family, whatever the price.
When a China visit does — and doesn't — make sense
We would rather lose the enquiry than sell a trip that cannot work. Here is the honest split.
Situations where it can genuinely make sense
- You already live in, or are moving to, China. Then none of the follow-up problem applies, the screening infrastructure is the best-resourced you will ever have access to, and the domestic cost figures above are the ones you will actually pay.
- A second opinion on a fast-progressing eye. A one-visit assessment at a high-volume tertiary centre — full cycloplegic refraction, biometry, and a treatment plan you take home — is a defensible reason to travel, precisely because it does not require ongoing local delivery.
- A paediatric surgical diagnosis, which is a different problem from myopia control: congenital cataract, congenital glaucoma, retinopathy of prematurity, paediatric keratoconus needing cross-linking, or strabismus. Here the case-volume argument for a large Chinese tertiary centre is real.
- Genuine unavailability at home — but verify it. Myopia-control spectacles and ortho-K are available in most high-income countries; check before assuming a flight is the only route.
Situations where it does not
- Starting ortho-K on a short trip. Fitting is iterative, and the first weeks need accessible review. Starting a fit you cannot return to is how a child ends up in an ill-fitting rigid lens worn overnight.
- Buying a red-light device to take home. Covered above: unsupervised use without OCT follow-up is outside current practice, and the regulator has moved in the direction of more oversight, not less.
- Stocking up on atropine drops. Concentration, duration and stopping are exactly the contested variables, and they need a prescriber who is watching the measurements.
- Anything framed as a cure. No intervention in this field reverses myopia or restores an eye to its pre-myopic length. Slowing growth is the whole of the goal.
If you do go: what to take home
The failure mode for international paediatric care is not the visit — it is the handover. Before you leave, ask for the full data set in a form a clinician at home can act on: cycloplegic refraction for both eyes, axial length in millimetres, corneal topography if lenses were discussed, the fundus and OCT images rather than a report describing them, and the treatment plan with its review interval written down. Insist that the child's name is transliterated correctly on the record at registration, because in Chinese hospital systems those details are difficult to change after a consultation and the error then propagates into everything you later want for insurance or continuity. Our guide to records and insurance for eye care abroad covers the mechanics, and eye surgery in China for foreigners covers English-language access and payment.
On where: the large public tertiary centres run the deepest paediatric subspecialty services. Zhongshan Ophthalmic Center in Guangzhou runs separate Paediatric Ophthalmology, Strabismus & Amblyopia, and Refraction & Myopia Control departments — and note the campus split, because those departments are not all at the same address. Shenzhen Eye Hospital runs dedicated strabismus, paediatric and myopia-control departments; our institutional guide sets out how to compare centres. Costs for the surgical paediatric diagnoses sit in the full China eye surgery price guide.
What we are not going to claim
Traditional-medicine adjuncts — acupoint massage, herbal preparations, eye-exercise regimens — are promoted in some provincial pilots and you may be offered them. Mainstream Chinese ophthalmology regards them as unproven for progression control rather than established therapy, and we will not describe them otherwise. Nor will we quote a China price for a myopia-control spectacle lens or a red-light device: we could not verify one, and a number invented today is a number somebody has to reconcile later. And no page, including this one, can tell you whether a particular child should be treated — that is a decision for a clinician who has measured the eye, more than once.
Frequently asked questions
Should we travel to China for our child's myopia control?
Usually no, and we would rather say so than sell a trip. Myopia control is not a procedure — it is a multi-year relationship built on measurements repeated every three to six months until the eye stops growing, and almost all of that has to happen where the child lives. A single visit abroad cannot deliver it. The narrow situations where a China visit does earn its cost are different: a family already living in or moving to China, a second opinion on a fast-progressing eye, a paediatric surgical diagnosis such as congenital cataract or congenital glaucoma, or access to a device or drug that genuinely is not obtainable at home — and even then the follow-up has to be arranged locally before you fly.
How much does orthokeratology cost in China?
A nationwide urban cost-of-illness survey published in 2022 put ortho-K and rigid gas-permeable lenses at a discounted mean of ¥4,673 per pair in Anhui, ¥5,902 in Shanghai and ¥6,466 in Yunnan, with lenses replaced roughly every 1.2 to 1.8 years and annual running costs of about ¥1,600–1,700 on top. Total annual cost per person came to ¥3,762 in Anhui, ¥5,822 in Shanghai and ¥5,670 in Yunnan — very roughly US$520–810 a year at ¥7.2 to the dollar. Those are domestic self-pay figures from a published survey, not international-department quotes, and international pricing at a private or VIP clinic runs higher. US ortho-K is commonly quoted at US$1,000–4,000 with a first-year average near US$2,000–2,800.
Is red-light therapy for myopia safe?
It is not settled, and the honest answer is that China's own regulator tightened rather than relaxed its position. Repeated low-level red-light therapy uses roughly 650 nm home devices and has produced strong efficacy signals in Chinese randomised trials. The laser emission is rated Class 1 under the IEC laser-safety standard, but Chinese researchers have reported reduced cone density near the fovea and drusen-like lesions in some children, and the NMPA reclassified these devices from Class II to Class III — its highest medical-device risk tier — effective July 2024, imposing national premarket review. Many clinicians now use RLRL only inside supervised protocols with OCT follow-up. A provider offering it as a consumer product without imaging follow-up is not following current practice.
Is low-dose atropine approved in China?
Yes. In March 2024 the NMPA granted a drug approval certificate to Xingqi Eye Medicine's atropine sulfate eye drops (SQ-729) for slowing myopia progression in children — the first myopia-control drug anywhere to receive a formal drug registration number on the basis of clinical-trial data, developed in the China Eye Valley cluster in Wenzhou. That does not settle the science. Trials still disagree: LAMP found a dose-dependent effect across 0.05%, 0.025% and 0.01%; CHAMP reported more responders on 0.01% than placebo (28.5% versus 17.5%); MOSAIC found 15.9% less progression and 17.5% less axial growth at two years; and PEDIG found no meaningful benefit of 0.01% over placebo. A 2025 randomised trial in JAMA Ophthalmology suggested 0.04% may outperform both orthokeratology and 0.01% on axial control.
Which myopia control treatment works best?
There is no single winner, and the strongest current practice is combination therapy pairing an optical method with a pharmacological one. On published trial data: highly aspherical lenslet spectacles reported 0.67 mm of axial growth over five years against 1.40 mm in controls; DIMS spectacles reported 59% less progression and 60% less axial elongation at two years; orthokeratology reduces axial elongation by roughly 30–60%, or about 0.25–0.27 mm over two years; low-concentration atropine at 0.01%–0.05% is well supported for delaying onset but contested on optimal concentration. Daily outdoor time remains the most cost-effective intervention in health-economics modelling. Which combination suits a particular child is a decision for the treating clinician, based on age of onset, measured axial length and rate of progression.
What number should we actually be tracking?
Axial length, not the spectacle prescription. The prescription is what the child needs to see; axial length is how much the eye has physically grown, and it is what predicts lifetime risk of retinal detachment, myopic maculopathy and glaucoma. Age of onset is the strongest single predictor of adult high myopia — a child who becomes myopic at seven or eight carries a lifetime high-myopia risk above 50%. Ask for axial length in millimetres at every visit, ask for the previous values, and ask how the rate compares with the age-specific growth curve. A clinic that measures only refraction cannot tell you whether treatment is working.
What does China's national myopia programme involve?
Screening at a scale attempted nowhere else, backed by inter-ministerial accountability since 2018. National monitoring shows childhood myopia prevalence fell 3.3 percentage points between 2018 and 2024, from a 2018 baseline of about 53.6%. In December 2025 thirteen departments issued the Children and Adolescents' Five Health Promotion Action Plan (2026–2030), setting targets of roughly 3% myopia among six-year-olds, below 32% in primary school, below 60% in junior secondary and below 70% in senior secondary. It mandates refractive screening at 24 and 36 months and at ages 4, 5 and 6, six-monthly screening in kindergarten and twice-per-semester screening in school, feeding electronic vision-health records — alongside at least two hours of daily outdoor time, screen-time limits and classroom lighting upgrades.
Are eye exercises or herbal treatments worth trying?
Mainstream Chinese ophthalmology treats traditional-medicine adjuncts as unproven for progression control, not established therapy, even though some provincial pilots promote them. They are unlikely to harm, but they are not a substitute for a measured treatment plan, and time spent on them is time not spent on the two things with the best evidence base behind them — daylight exposure and an optical or pharmacological intervention chosen from your child's actual numbers.